In conclusion, the evidence we provided for the expression and functional role of the CSF-1/CSF-1R pair in breast cancer, together with the established role of CSF-1/CSF-1R in breast cancer motility and invasiveness [29]–[31], indicate that CSF-1R targeting may be pursued therapeutically, irrespective of breast cancer subtype, at either early or late stages of tumor progression. This evidence concerns the gene CSF1 and neoplasm.